Xenon Pharmaceuticals (XENE) to Offer Common Stock

Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an additional 15% of the common shares offered in the offering, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Definium Therapeutics plans $500M public share offering
• Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings